SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17964)3/26/1998 11:11:00 PM
From: Russian Bear  Read Replies (2) | Respond to of 32384
 
Henry,

A "p" of 0.00003 is pretty darn good, wouldn't you say? I would be highly surprised if the FDA didn't conduct an expedited review, given the safety profile and clear efficacy data. KS is a gravely serious condition, after all.

As for the TSE424 IND, do you know, off hand, the order of magnitude of the AHP milestone payment? Also, is it supposed to be a straight payment, or an equity purchase of some sort?

Thanks, as always,
RB

P.S. Does anyone have access to Instanet? I would be curious to know the initial reaction to the news. (I would guess that the reaction will be positive.)



To: Henry Niman who wrote (17964)3/26/1998 11:32:00 PM
From: Machaon  Read Replies (1) | Respond to of 32384
 
Henry, I know that "off-label" has been discussed quite a bit.

But, hopefully not rehashing old notes, how strong is an argument that Panretin's effectiveness against Kaposi's Sarcoma could also be as effective against basal cell carcinoma, squamous cell carcinoma or malignant melanoma?

Are these four different cancers totally different animals?

These other cancers represent much larger markets.

Thanks, Bob


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News